Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 12/20 | 0.62 |
| ▸ | GSK3B | P49841 | 12/20 | 0.62 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917637 | 0.95 | GSK3A (0.69) | GSK3AGSK3BIGF1RJAK2RET | |
| SCHEMBL11917635 | 0.95 | GSK3A (0.66) | GSK3AGSK3BIGF1RJAK2RET | |
| SCHEMBL11917636 | 0.94 | GSK3A (0.70) | GSK3AGSK3BIGF1RJAK2RET | |
| SCHEMBL11917638 | 0.94 | GSK3A (0.70) | GSK3AGSK3BIGF1RJAK2RET | |
| SCHEMBL11917640 | 0.92 | GSK3A (0.71) | GSK3AGSK3BIGF1RRET | |
| SCHEMBL11917632 | 0.92 | GSK3A (0.56) | GSK3AGSK3BIGF1RJAK2RET | |
| SCHEMBL11917641 | 0.85 | GSK3A (0.71) | GSK3AGSK3BIGF1RJAK2RET | |
| SCHEMBL3139887 | 0.82 | GSK3A (0.54) | GSK3AGSK3BIGF1RJAK2NTRK1 | |
| SCHEMBL12303090 | 0.81 | GSK3A (0.89) | GSK3AGSK3BIGF1RNTRK1 | |
| SCHEMBL11917645 | 0.79 | GSK3A (0.72) | GSK3AGSK3BJAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194444-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-10 | — | — | US | disclosed |
| US-20140194444-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-10 | — | — | US | disclosed |
| US-8664219-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664219-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-8242272-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242272-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110020376-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020376-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-22 | — | — | US | disclosed |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-22 | — | — | US | disclosed |
| WO-2009145814-A9 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009145814-A2 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020376-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKDC, MAP3K5, MAP3K20 | GSK3A 331/4885GSK3B 371/4885IGF1R 2469/4885 |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885IGF1R 3065/4885 |
| US-20140194444-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKDC, MAP3K5, MAP3K20 | GSK3A 331/4885GSK3B 371/4885IGF1R 2469/4885 |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885IGF1R 3065/4885 |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | GSK3B, CDK3, GSK3A | GSK3A 3/4885GSK3B 1/4885IGF1R 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.